BCLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Brainstorm Cell Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.064. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.62 for the trailing ten years ended in Dec. 2023.
During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -8.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -12.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Brainstorm Cell Therapeutics was 17.00% per year. The lowest was -15.20% per year. And the median was 1.70% per year.
As of today (2024-05-14), Brainstorm Cell Therapeutics's current stock price is $0.5001. Brainstorm Cell Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-0.62. Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Brainstorm Cell Therapeutics's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | -0.60 | -0.61 | -0.62 | -0.63 | -0.62 |
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Brainstorm Cell Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.064 | / | 129.4194 | * | 129.4194 | |
= | -0.064 |
Current CPI (Dec. 2023) = 129.4194.
Brainstorm Cell Therapeutics Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | -0.041 | 99.695 | -0.053 |
201406 | -0.078 | 100.560 | -0.100 |
201409 | -0.074 | 100.428 | -0.095 |
201412 | -0.131 | 99.070 | -0.171 |
201503 | -0.107 | 99.621 | -0.139 |
201506 | -0.090 | 100.684 | -0.116 |
201509 | -0.138 | 100.392 | -0.178 |
201512 | -0.070 | 99.792 | -0.091 |
201603 | -0.161 | 100.470 | -0.207 |
201606 | -0.079 | 101.688 | -0.101 |
201609 | -0.015 | 101.861 | -0.019 |
201612 | -0.064 | 101.863 | -0.081 |
201703 | -0.088 | 102.862 | -0.111 |
201706 | -0.089 | 103.349 | -0.111 |
201709 | 0.200 | 104.136 | 0.249 |
201712 | -0.159 | 104.011 | -0.198 |
201803 | -0.114 | 105.290 | -0.140 |
201806 | -0.008 | 106.317 | -0.010 |
201809 | -0.319 | 106.507 | -0.388 |
201812 | -0.185 | 105.998 | -0.226 |
201903 | -0.040 | 107.251 | -0.048 |
201906 | -0.163 | 108.070 | -0.195 |
201909 | -0.168 | 108.329 | -0.201 |
201912 | -0.159 | 108.420 | -0.190 |
202003 | -0.529 | 108.902 | -0.629 |
202006 | -0.195 | 108.767 | -0.232 |
202009 | -0.225 | 109.815 | -0.265 |
202012 | -0.235 | 109.897 | -0.277 |
202103 | -0.251 | 111.754 | -0.291 |
202106 | -0.147 | 114.631 | -0.166 |
202109 | -0.184 | 115.734 | -0.206 |
202112 | -0.153 | 117.630 | -0.168 |
202203 | -0.101 | 121.301 | -0.108 |
202206 | -0.169 | 125.017 | -0.175 |
202209 | -0.133 | 125.227 | -0.137 |
202212 | -0.127 | 125.222 | -0.131 |
202303 | -0.109 | 127.348 | -0.111 |
202306 | -0.171 | 128.729 | -0.172 |
202309 | -0.145 | 129.860 | -0.145 |
202312 | -0.064 | 129.419 | -0.064 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Stacy Lindborg | officer: EVP, Head Global Clin Research | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Nir Naor | director | BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Kirk Taylor | officer: Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Menghisteab Bairu | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Alla Patlis | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Anthony Waclawski | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Chaim Lebovits | officer: Chief Executive Officer | 110 EAST 59TH STREET, NEW YORK NY 10019 |
David Setboun | officer: EVP and COO | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Acc International Holdings Ltd. | other: Member of 10% owner group | MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110 |
Sankesh Abbhi | director | 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134 |
Jacob A Frenkel | director | 188 E. 70TH ST., #29A, NEW YORK NY 10021 |
Arturo Araya | officer: Chief Commercial Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Preetam Shah | officer: EVP, CFO and Treasurer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Ralph Dr. Kern | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Irit Arbel | director | 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000 |
From GuruFocus
By PRNewswire • 12-14-2023
By PRNewswire • 12-19-2023
By PRNewswire • 12-08-2023
By PRNewswire • 12-15-2023
By PRNewswire • 12-06-2023
By PRNewswire • 12-10-2023
By PRNewswire • 12-27-2023
By PRNewswire • 12-01-2023